Andrew John Partridge, the Chief Growth Officer of GRAIL, Inc., has reported the sale of 7,873 shares of the company's common stock. This transaction, filed on October 7, 2026, is significant as it reflects ongoing financial activity within GRAIL and the broader medical laboratories sector.
Background
GRAIL, Inc. is a company focused on early cancer detection, operating under the SIC code for medical laboratories (8071). The firm is incorporated in Delaware and is publicly traded under the ticker symbol GRAL. Recent filings indicate that GRAIL has been active in the market, with several transactions reported in the past few months.
What the Filing Says
The filing states that the transaction occurred on October 5, 2026, with a reported price of $146.39 per share. The filing notes, "Represents automatic 'sell-to-cover' transactions by an executing broker to cover withholding taxes upon award vesting and share delivery." Following this transaction, Partridge now owns 155,865 shares of GRAIL.
Impact
This sale may affect GRAIL's stakeholders, including investors and employees, as it reflects the company's ongoing financial maneuvers. The medical laboratories sector remains competitive, and transparency in executive transactions is crucial for maintaining investor trust.
What's Next
The filing does not say what happens next.